

# An Epidemic of Methicillin-Resistant *Staphylococcus aureus* Soft Tissue Infections Among Medically Underserved Patients

David M. Young, MD; Hobart W. Harris, MD, MPH; Edwin D. Charlebois, MPH, PhD; Henry Chambers, MD; Andre Campbell, MD; Françoise Perdreau-Remington, PhD; Chen Lee, MD; Mahesh Mankani, MD; Robert Mackersie, MD; William P. Schecter, MD

**Hypothesis:** A high prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) in soft tissue infections presents a treatment challenge.

**Design:** Retrospective analysis.

**Setting:** The San Francisco General Hospital Integrated Soft Tissue Infection (ISIS) Clinic.

**Patients:** Patients treated at the ISIS Clinic from July 1, 2000, to June 30, 2003.

**Main Outcome Measures:** Information on patient demographics, surgical procedures, microbiologic studies, and antibiotic treatments was obtained for all patients treated in the ISIS Clinic. Microbial data and antibiotic susceptibility pattern of *S aureus*, treatment outcome, and antibiotic prescribed were analyzed for all evaluable patients.

**Results:** The ISIS Clinic treated 6156 unique patients for 12012 episodes of infection. In this cohort, 5164 (84%) were either homeless or had no health insurance. More than half of the patients (58%) were injection drug users, but most had only 1 prior visit to the clinic (62%). Patients underwent a surgical procedure 7707 times (64%). Of the 837 positive cultures obtained, *S aureus*

was recovered 695 times (83%), and 525 (63%) of the cultures contained MRSA. Therefore, a full 76% of all *S aureus* isolated was MRSA. In a subset analysis of 622 cultures collected prospectively from consecutive patients, 282 (45%) grew organisms, of which 256 (91%) were *S aureus*. MRSA represented 59% of all *S aureus* isolated. Homelessness and injection drug use were risk factors for infection by *S aureus* and MRSA. In another subgroup of patients with soft tissue infections that required admission to the hospital, MRSA was recovered from the cultures in 149 patients. In these patients with MRSA, 44 (30%) only received a  $\beta$ -lactam antibiotic, inactive against MRSA, and had full resolution of their infection.

**Conclusions:** The prevalence of MRSA soft tissue infections in the medically underserved ISIS Clinic cohort is extremely high. The transmission of the MRSA seems to be in the community. Antibiotic therapy directed at MRSA may not be needed in a large number of patients with these soft tissue infections. Studies to identify the source and cause of this MRSA outbreak are urgently needed. Clinical trials to examine the need for antibiotic therapy in soft tissue infections should be conducted.

*Arch Surg.* 2004;139:947-953

From the Department of Surgery, San Francisco General Hospital, University of California, San Francisco (Drs Young, Harris, Campbell, Mankani, Mackersie, and Schecter); Department of Medicine, Division of Infectious Diseases, Epidemiology, and Prevention, Interventions Center, San Francisco General Hospital, University of California, San Francisco (Drs Charlebois, Chambers, and Perdreau-Remington); and Department of Surgery, McGill University School of Medicine, Montreal, Quebec (Dr Lee).

**B**ACTERIAL RESISTANCE TO ANTIBIOTICS is an increasing problem in soft tissue infections.<sup>1</sup> *Staphylococcus aureus* is the most common organism cultured in soft tissue infections, and resistance of *S aureus* to  $\beta$ -lactam antibiotics or methicillin-resistant *S aureus* (MRSA) has been an increasing problem.<sup>2</sup> Initially, MRSA was described as a nosocomial pathogen and a problem confined to institutionalized patients.<sup>3-5</sup> More recently, spread of MRSA to the community setting has been described in injection drug users,<sup>6-8</sup> prisoners,<sup>9</sup> and children.<sup>10,11</sup> The prevalence of MRSA in community-acquired soft tissue infec-

tions seems to be increasing rapidly worldwide.<sup>12-16</sup> Even though MRSA soft tissue infections are no more severe than infections caused by methicillin-sensitive *S aureus*, antibiotic treatments are more limited in MRSA infections and create special problems in treatment.

The Integrated Soft Tissue Infection (ISIS) Clinic is a specialized center established to treat the large number of soft tissue infections found in the medically underserved, inner-city population of San Francisco, Calif.<sup>17</sup> The ISIS Clinic offers a unique opportunity to observe the natural history of soft tissue infections in a large cohort of patients in a longitudinal fashion. The ISIS Clinic started treating pa-

**Table 1. Demographic Summary of the Integrated Soft Tissue Infection Clinic Cohort\***

Variable	Patients, No. (%)
Total patients	6156
Total visits	12 012
Female	1857 (30)
Male	4299 (70)
Ethnicity	
White	2542 (41)
African American	1907 (31)
Hispanic	1150 (19)
Native American	35 (1)
Asian	402 (7)
Other	89 (1)
Unknown	31 (1)
Uninsured	4980 (81)
Homeless	1876 (30)
Homeless or uninsured	5164 (84)

\*The mean age of patients was 42 years (range, 1-89 years).

tients July 2000 and since that time has provided uninterrupted, 7-day-per-week treatment for all patients on a walk-in basis.

To our knowledge, previous studies have not reported the prevalence of MRSA in soft tissue infections in such a large cohort in the community setting. Therefore, the data collected from the ISIS Clinic cohort was used to estimate the prevalence of MRSA in this medically underserved population. Although this cohort may not reflect the population as a whole, certain generalizations can be made about the prevalence of MRSA in the medically underserved population.

## METHODS

### PATIENT SELECTION

The San Francisco General Hospital ISIS Clinic, with the goal of providing compassionate, efficient, and cost-effective care to all patients with soft tissue infections within San Francisco County, has been in operation since July 2000. In addition to rendering timely medical care, the clinic was designed to provide access to other relevant services, including substance abuse counseling and treatment, selected social services, and wound care. The clinic is open every day, treats patients on a walk-in, first-come-first-serve basis, and is staffed by academic faculty surgeons, licensed nurses, a substance abuse counselor, a social worker, and an administrative support person. This retrospective analysis of the ISIS Clinic cohort encompasses the 3-year period from July 1, 2000, to June 30, 2003. The ISIS Clinic database was reviewed for information on patient demographics, surgical procedures, microbiologic studies, and drug prescriptions.

### MICROBIOLOGIC CULTURES AND SUSCEPTIBILITY TESTING

Routine cultures were not obtained from the patients in the ISIS Clinic, because treatment decisions were not based on culture results, and the cost of culturing every patient was prohibitive. Instead, periodic surveillance of the microbiologic profile was performed in this population to characterize the nature of the infections in the ISIS Clinic cohort. Wound cultures were obtained from patients undergoing procedures for drain-

age of abscesses. The intact skin over the abscess was cleansed with 10% povidone-iodine solution (Smith and Nephew, Largo, Fla) before incision or debridement. A sterile Dacron swab (Becton, Dickinson & Co, Cockeysville, Md) was rotated within the cavity immediately after surgical incision. Swabs were then sent to the San Francisco General Hospital clinical microbiology laboratory for routine aerobic and anaerobic culture and antimicrobial susceptibility testing. Incubation of trays and determination of minimum inhibitory concentrations were performed (Microscan Walkaway instrument; Dad International, West Sacramento, Calif). Guidelines from the National Committee on Clinical Laboratory Standards were used throughout to assess susceptibility.<sup>18</sup>

A risk factor analysis was performed on a subset of the first 666 patients with procedures performed using recovery of *S aureus* and MRSA as the dependent (outcome) variables. Independent (predictor) variables evaluated included age, sex, race/ethnicity, injection drug use, and homelessness.

Research using human subjects was approved by the University of California, San Francisco, Committee on Human Research, holding federal-wide assurance from the Office for Human Research Protections (No. FWA-0000068).

## STATISTICAL ANALYSIS

Prevalence was calculated using standard equations.<sup>19</sup> The Fisher exact test was used to test for significant associations between categorical variables.<sup>20</sup> Odds ratios (ORs) and significance testing for *S aureus* prevalence and methicillin resistance were obtained using logistic regression as implemented in the SAS statistical software package.<sup>21</sup>

## RESULTS

The ISIS Clinic treats a considerable number of patients with soft tissue infections who have limited access to health care and little financial resources. In the 3-year period from July 1, 2000, through June 31, 2003, the clinic treated 6156 unique patients for a total of 12 012 visits (**Table 1**). There were 4299 men (70%), and the patients had a median age of 42 years (age range, 1-89 years). The racial distribution of the patients is similar to that of the local community. There were 4980 patients (81%) without health insurance coverage, and 1876 (30%) were homeless. A larger number of people lived in marginal situations, such as residential hotels, or stayed with friends, families, or acquaintances but were not considered homeless because they could provide an address. A total of 5164 patients (84%) were either without health care insurance coverage or homeless, indicating that the ISIS Clinic cohort represents a patient population with limited access to health care and financial resources and who are typically regarded as medically underserved.

Most patients had *S aureus* infections, and most of the isolates in these patients were resistant to methicillin (**Table 2**). In the study period, 837 positive cultures were obtained. A total of 695 cultures (83%) contained *S aureus*, and 525 cultures (63%) contained MRSA. Most *S aureus* isolates were MRSA (76%). Because the total number of cultures obtained (including cultures that did not grow organisms) was not available in the database and the clinical reasons for submitting these cultures was not always clear, this group may represent a heterogeneous group of patients within the ISIS Clinic cohort, and these data may represent a biased sample. Therefore, a subgroup of

patients who underwent microbiologic evaluation in a prospective study was analyzed.

In a prospective study, the rate of MRSA was lower, but still a very high percentage of patients had MRSA (59%). A group of 622 consecutive patients who underwent incision and drainage of an abscess in the ISIS Clinic had a bacterial culture obtained (Table 2). Within this group, information on both positive and negative culture findings was available. A total of 282 (45%) of the cultures obtained grew organisms. *Staphylococcus aureus* was found in 256 (91%) of all positive culture findings, and 150 (59%) of these were MRSA. The recovery rate of positive culture results in this study (45%) was lower than that generally reported, so our estimate of the prevalence of MRSA of 24% in all cultures obtained from the ISIS Clinic cohort may be an underestimation. Still, MRSA was found in 59% of all cultures positive for *S aureus*, making MRSA the predominant isolate in these infections.

This MRSA outbreak in the ISIS Clinic cohort seems to be community acquired and may be related to the unique environment of these patients. Although a large portion of the patient population had prior visits to the ISIS Clinic (2047 [33%] had 2-5 visits, and 291 [5%] had more than 5 visits), most patients were seen for the first time (3818 [62%]). Thus, the MRSA from these patients was isolated from a first visit and did not represent the spreading of MRSA from contact within the ISIS Clinic. The patients' environment also played a role in infection with *S aureus*. Most patients (58%) admitted that the injection of heroin was the direct cause of the infection. The other risk factor was homelessness. In the subset of the first 666 patients with microbiologic culture results, injection drug users had an OR of 1.4 for *S aureus* compared with patients who did not inject drugs ( $P=.04$ ), and homeless patients had an OR of 1.4 for *S aureus* compared with patients with stable living situations ( $P=.04$ ). A risk factor for recovery of MRSA from patients was also associated with injection drug use (OR, 1.8;  $P=.003$ ) and homelessness (OR, 1.5;  $P=.03$ ).

One potential reason for the large number of patients infected with MRSA is the widespread use or overuse of antibiotics in this population. We examined the clinical records of the infections treated and determined that the magnitude of the infections seen in the ISIS Clinic was clinically significant and substantial enough to warrant treatment with antibiotics by current standards. Incision and drainage of an abscess or debridement of the wound was used to treat most infections (7707 [64%]). The average area of the abscess with surrounding cellulitis was 25 cm<sup>2</sup>, and the average amount of pus drained from each abscess was 15 mL (Figure). In a review of the medical records, we discovered that nearly all patients seen in the ISIS Clinic were given antibiotic therapy (>95%). By present medical standards, the patients treated in the ISIS Clinic appeared to require antibiotic therapy, but whether the antibiotics were required for resolution of the infection is an important and unanswered question.

As an initial attempt to determine the efficacy of antibiotics in the treatment of soft tissue infections, a retrospective analysis of the antibiotic therapy matched to the microbiologic isolate was performed in the ISIS Clinic cohort. Although most ISIS Clinic patients were treated

**Table 2. Microbiology Results From the ISIS Clinic Cohort**

Result	No. (%)
Entire ISIS cohort	
Total surgical procedures	7707
Positive culture findings	837 (11)
Cultures with <i>Staphylococcus aureus</i>	695 (83)
MRSA	525 (63)
MRSA in all cultures positive for <i>S aureus</i>	525 (76)
Prospective surveillance	
Total cultures obtained	622
Positive culture findings	282 (45)
Cultures with <i>S aureus</i>	256 (91)
MRSA	150 (59)
MRSA in all cultures obtained	150 (24)
MRSA in all cultures positive for <i>S aureus</i>	150 (59)

Abbreviations: ISIS, Integrated Soft Tissue Infection; MRSA, methicillin-resistant *Staphylococcus aureus*.



Typical San Francisco General Hospital Integrated Soft Tissue Infection Clinic patient with methicillin-resistant *Staphylococcus aureus* soft tissue infection treated with surgical drainage and cefazolin.

solely as outpatients, a subgroup of 2042 patients (17%) had infections deemed severe enough to warrant admission for intravenous antibiotic therapy and close clinical observation. Only patients who had successful treatment of their soft tissue infections were included. From this subgroup, microbiologic data were available from 149 (7%) of these inpatients, and the antibiotic therapy administered was obtained from the hospital pharmacy database. Of this subgroup, 105 (70%) had adequate antibiotic treatment; however, a considerable number of patients (44 [30%]) infected with MRSA were given only antibiotics that were not effective against the organism. By far the most common scenarios were patients with MRSA treated with cefazolin (19 [43%]) or ticarcillin cresyl sodium and clavulanate potassium (17 [39%]). Despite the treatment of MRSA with a presumably ineffective antibiotic, all of these infections resolved.

#### COMMENT

Previous studies have described an increasing rate of community-acquired soft tissue infections related to MRSA, but none to our knowledge have described such a high rate as found in the ISIS Clinic cohort. This alarmingly

high rate may be due to the particular characteristics of this medically underserved population. Often these patients undergo treatment for multiple bouts of infection that may select for resistant organisms. However, prior treatment cannot completely explain the epidemic of MRSA infections. Certainly, injection drug use is a risk factor for soft tissue infections.<sup>7</sup> Homelessness and inadequate access to health care for these patients are also risk factors. Yet factors that lead to the selection of organisms resistant to antibiotics have not been clearly identified. Once these resistant strains are embedded in this population, poor hygiene and inadequate living conditions probably lead to transmission and colonization of the MRSA strains in these patients in the community. Then the prevalence of the organism in soft tissue infection is a reflection of the prevalence of the colonizing organism. Studies to identify the source and cause of this MRSA outbreak are urgently needed.

Antibiotic use in soft tissue infections is widespread and may contribute to such a high rate of MRSA in this population. Most patients treated in the ISIS Clinic and in other clinics operated by the San Francisco Department of Public Health present with clinical signs of infection that warrant treatment with antibiotics.<sup>22</sup> Most patients with soft tissue infections are prescribed a  $\beta$ -lactam antibiotic (cephalexin or dicloxacillin). The widespread availability of antibiotics has created a culture of antibiotic use in the community. Patients frequently report self-medication with antibiotics obtained from friends or purchased on the street. Patients frequently arrive in the clinics demanding antibiotics for lesions and conditions that clinicians would not treat with antibiotics. Clinicians have even reported prescribing antibiotics to these patients because the time spent trying to convince patients that they do not need antibiotics was too demanding. Such frequent use of antibiotics in this population may or may not be needed to treat these infections but certainly can contribute to an increase in antibiotic-resistant strains.

Furthermore, retrospective data from the ISIS Clinic cohort suggests that antibiotics may be overused in treating these infections, even by knowledgeable clinicians. In the subgroup of ISIS Clinic patients with the most serious infections (patients who require admission), 30% recovered uneventfully from their infections with treatment by antibiotics that were ineffective against the organism recovered from the infection. However, some of these infections were polymicrobial and also contained streptococcal species that were sensitive to  $\beta$ -lactam antibiotics. Some clinicians have argued that  $\beta$ -lactam antibiotics may kill the sensitive organisms in the soft tissue infection and tip the balance in favor of the body's host defenses against the organisms that are resistant to the antibiotic given. The continued use of  $\beta$ -lactam antibiotics in patients who are most likely infected by MRSA raises a serious point of debate among the clinicians who treat patients in the ISIS Clinic cohort. Despite review of the data presented herein, the clinicians decided to continue treating these patients with  $\beta$ -lactam antibiotics. Because of the lack of data from well-designed clinical trials, the clinicians fear that changing the present practice pattern may adversely change clinical outcomes.<sup>22</sup>

Clinical trials in this patient population are clearly needed to determine whether the use of  $\beta$ -lactam antibiotics is really beneficial in these soft tissue infections. A randomized, double-blind, placebo-controlled trial to compare ceftazolin with an agent known to be effective against MRSA (vancomycin) is currently under way. Previous discussions about conducting a placebo-based trial were rejected as too risky, but our retrospective analysis of antibiotic use and outcomes in the ISIS Clinic cohort has made such a trial more imperative. Understanding the relationship between antibiotic treatments, emergence of resistance, and clinical outcomes will certainly lead to more rational use of antibiotics in the future.

The emergence of MRSA in community-acquired soft tissue infections is more significant but certainly not isolated to the medically underserved patients found in the ISIS Clinic cohort.<sup>16</sup> This medically underserved population likely represents the beginning of a wider epidemic of MRSA soft tissue infections in the general population. The ISIS Clinic population may serve as a reservoir of MRSA in the community and continue to challenge health care services for these people and the community at large. Addressing widespread multidrug resistance bacterial infections with rationally designed clinical trials will lead to a better understanding of the pathophysiology of soft tissue infections and to better medical care.

*Accepted for publication May 21, 2004.*

*This study was supported in part by the Hellman Family Award for Early Career Faculty and in part by the Doris Duke Charitable Foundation, Reston, Va (Dr Charlebois); by grants AI43959 and AI46610 from the US Public Health Service, Washington, DC (Dr Chambers); and the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, Md.*

*This paper was presented at the 75th annual meeting of the Pacific Coast Surgery Association; February 16, 2004; Wailea, Hawaii; and is published after peer review and revision. The discussions that follow this article are based on the originally submitted manuscript and not the revised manuscript.*

*Dr Charlebois was the validating statistician.*

*We thank Anson Moon, MSW, Allan Huang, BA, and Margaret Wong, MA, for their help with database analysis. Jan Horn provided helpful suggestions during preparation of the manuscript.*

*Correspondence: David M. Young, MD, Department of Surgery, San Francisco General Hospital, 1001 Potrero Ave, NB3A, San Francisco, CA 94110 (dyoung@sfghsurg.ucsf.edu).*

## REFERENCES

1. Marchese A, Schito GC, Debbia EA. Evolution of antibiotic resistance in gram-positive pathogens. *J Chemother.* 2000;12:459-462.
2. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. *Int J Antimicrob Agents.* 2003;22:406-419.
3. Terpenning MS, Bradley SF, Wan JY, Chenoweth CE, Jorgensen KA, Kauffman CA. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. *J Am Geriatr Soc.* 1994;42:1062-1069.

4. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant *Staphylococcus aureus* in hospitalized adults and children without known risk factors. *Clin Infect Dis*. 1999;29:797-800.
5. Saiman L, O'Keefe M, Graham PL III, et al. Hospital transmission of community-acquired methicillin-resistant *Staphylococcus aureus* among postpartum women. *Clin Infect Dis*. 2003;37:1313-1319.
6. Fleisch F, Zbinden R, Vanoli C, Ruef C. Epidemic spread of a single clone of methicillin-resistant *Staphylococcus aureus* among injection drug users in Zurich, Switzerland. *Clin Infect Dis*. 2001;32:581-586.
7. Charlebois ED, Bangsberg DR, Moss NJ, et al. Population-based community prevalence of methicillin-resistant *Staphylococcus aureus* in the urban poor of San Francisco. *Clin Infect Dis*. 2002;34:425-433.
8. Ciccarone D, Bamberger J, Kral A, et al. Soft tissue infections among injection drug users—San Francisco, California, 1996-2000. *JAMA*. 2001;285:2707-2709.
9. Methicillin-resistant *Staphylococcus aureus* infections in correctional facilities—Georgia, California, and Texas, 2001-2003. *MMWR Morb Mortal Wkly Rep*. 2003;52:992-996.
10. Marcinak JF, Frank AL. Treatment of community-acquired methicillin-resistant *Staphylococcus aureus* in children. *Curr Opin Infect Dis*. 2003;16:265-269.
11. Fergie JE, Purcell K. Community-acquired methicillin-resistant *Staphylococcus aureus* infections in south Texas children. *Pediatr Infect Dis J*. 2001;20:860-863.
12. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant *Staphylococcus aureus* infection. *JAMA*. 2003;290:2976-2984.
13. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant *Staphylococcus aureus*: an emerging pathogen. *Infect Control Hosp Epidemiol*. 2003;24:451-455.
14. Methicillin-resistant *Staphylococcus aureus* infections among competitive sports participants—Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. *MMWR Morb Mortal Wkly Rep*. 2003;52:793-795.
15. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant *Staphylococcus aureus* infections in France: emergence of a single clone that produces Pantone-Valentine leukocidin. *Clin Infect Dis*. 2002;35:819-824.
16. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant *Staphylococcus aureus*—an emerging problem for the management of skin and soft tissue infections. *Curr Opin Infect Dis*. 2003;16:103-124.
17. Harris HW, Young DM. Care of injection drug users with soft tissue infections in San Francisco, California. *Arch Surg*. 2002;137:1217-1222.
18. National Committee on Clinical Laboratory Standards. *NCCLS 2000 Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically*. Approved standard, 5th ed. Wayne, Pa: National Committee on Clinical Laboratory Standards; 1994:14(16). Document M7-A5 NCCLS.
19. Fleiss J. *Statistical Methods for Rates and Proportions*. 2nd ed. New York, NY: John Wiley & Sons; 1981.
20. Agresti A. A survey of exact inference for contingency tables. *Stat Sci*. 1992;7:131-153.
21. *The SAS Statistical Analysis System* [computer program]. Version 8. Cary, NC: SAS Institute; 1999.
22. Bamberger J. *Skin and Soft Tissue Infection Taskforce: Antibiotic Prescribing Practices*. San Francisco, Calif: Dept of Public Health; January 26, 2004.

## DISCUSSION

**Claude H. Organ, Jr, MD, Oakland, Calif:** I congratulate Dr Young and his associates from the San Francisco General Hospital for this important contribution and the Program Committee for placing it on the program. Several years ago, Marshall Orloff stated that he always found a nugget that he could take back home from this meeting that would help him in his clinical practice. Drs Young, Harris, Schecter, and their colleagues have carefully defined an interesting clinical problem in a subset of patients with soft tissue infections characterized by methicillin-resistant *Staphylococcus aureus*.

This presentation by the San Francisco General Hospital group is a follow-up report to their lead article in the *Archives of Surgery* in November 2002. I would venture that of all of the creative things that have come from San Francisco General, including emergency room thoracotomies, thumb tacking for severe pelvic vascular injuries, etc, this is probably the more important and useful one.

Although I have some concern about defining bacteria relating to their resistance to specific antibiotics, such as methicillin and vancomycin, nevertheless, it is a part of our jargon and is not destined to disappear in the future.

In their presentation, they have treated a cohort of 6000 patients with 12000 infection episodes. The predictive factors as outlined are not surprising. Eighty-one percent had no health insurance, 84% were either homeless or had no health insurance, and males predominated. Regrettably, these are the shameful facts of our times. Eighty-three percent of this cohort's subset of patients' cultures were *Staph aureus* of which 63% were methicillin resistant. I concur with their conclusions regarding the overuse of antibiotics in today's practices. Certainly, we know that  $\beta$ -lactam antibiotics used to treat MRSA are inactive and expensive. The overuse of antibiotics is convincingly documented in this manuscript, and we should take notice. A 33% recidivism rate is consistent with reports elsewhere.

There are 2 take-home messages in this manuscript. First, incision and drainage of abscesses may very well be the only thing that is needed and expensive antibiotics are not needed. Second, you should visit this ISIS Clinic. It is sensibly designed, clinically effective, and multidisciplinary and has the support of their administration. With these cost-effective figures, it is something you can take back to your administration. It is a creative solution to an expensive problem that takes the strain off of our operating rooms and a number of other cost-effective measures.

The ISIS Clinic is a nugget you can appreciate at your institution and is a small operation and not complex. Going to their ISIS Clinic and meeting the nurse coordinator is worth a visit, because she is really a dynamic individual. In future studies, do you plan to perform additional pulse gel electrophoresis and staphylococcal gene testing?

I have followed this with a great deal of admiration. Your immediate problem, however, is to survive the *Archives of Surgery* peer review process. Good luck!

**Daniel R. Margulies, MD, Los Angeles, Calif:** I enjoyed this paper, and I appreciate your bringing our attention to this increasing resistance of antibiotic-resistant bacteria in the outpatient setting. I wonder specifically if you could tell us how you dealt with these infections. Did you drain them in an outpatient setting and not treat with antibiotics, or were these patients then admitted for antibiotics according to the severity? We found that our methicillin-resistant *Staphylococcus aureus* is actually sensitive to Bactrim, and we have used this as an inexpensive way to treat outpatient infections that need antibiotics.

**Stephen G. Jolley, MD, Anchorage, Alaska:** We have a real problem with the Alaskan native population in terms of methicillin-resistant *Staphylococcus aureus*. About 80% of the *Staph aureus* that we isolate is methicillin resistant. It has a little different sensitivity spectrum though. The MRSA we see in the Alaska native population is sensitive to not only Bactrim but also clindamycin and rifampin, as well as vancomycin. The question I have for the authors is do you have a similar sensitivity spectrum to our population, or are your MRSA only sensitive to vancomycin? Although our native population has access to medical care and they do have health care coverage, we don't think that they necessarily get an exposure to too many antibiotics.

**Roger E. Alberty, MD, Portland, Ore:** This paper is of interest to me from a historical point of view. Our forbearers used to call this laudable pus. They had survived the period of strep infection, which they could do nothing about in the preantibiotic era, and had gotten to where they had a staph infection in which they had considerable success with simple incision and drainage. The data here revisit that old issue.

In the Portland area, we have encountered major problems with orthopedic procedures with methicillin-resistant staph,

and our citywide infectious disease specialists have identified the source as nursing homes, assisted living, and other similar facilities. Seventy percent of the patients in those facilities have methicillin-resistant staph. Coming into our hospitals, they bring it with them. So it is not just an inner-city problem; it is a problem I think for virtually every hospital.

**Ralph W. Aye, MD, Seattle, Wash:** We found that heroin users like being in the hospital, especially a private hospital where the nurses are more naive and they can get narcotics for their dressing changes. So my question is whether the ISIS Clinic is a hospital policy or whether that represents a citywide policy, whether you have seen any of the sort of patient shifting that we see going on in the Seattle area.

**Robert J. Albo, MD, Oakland:** As a member of the staff that cares for national football league injuries, this last year has resulted in an outbreak of MRSA in professional football players who have been injured primarily on artificial turf but not necessarily so. As you probably are well aware, there are many scrapes and lacerations that occur during a football game, and this year there have actually been several admissions of ill players from MRSA infection as well as several players who have missed football games and had to be treated for a period to get rid of infections. This is something entirely new, and a league-wide paper will be reported this next week at the official combined meeting of the NFL. So this is not just being seen in hospital-acquired populations or drug-related infections that are expected, but it is being seen in the general public and particularly now in an almost epidemic form in professional football.

**Samuel Eric Wilson, MD, Orange, Calif:** Methicillin-resistant *Staph aureus* has been thought to have emerged in acute care hospitals as a result of antimicrobial pressure and to have entered the community via chronic care facilities and perhaps carriage by health care workers. However, your genotype study suggests a community origin for the MRSA in your patients and a different resistance pattern, which allows treatment with routine antimicrobials. I wish to emphasize that one could not extend these observations to nosocomial MRSA infection. Do you, in fact, make this differentiation in your practice between the community-acquired infection and the multidrug-resistant, hospital-acquired organism? The difference in prognosis is major, and it is critical to use appropriate agents for hospital-acquired MRSA infection.

**Dr Campbell:** I appreciate the privilege of the floor this morning to respond to the questions from the discussants. I would also like to thank Dr Organ for his insightful comments regarding the ISIS Clinic.

I would like to say a bit about the ISIS Clinic. The clinic has really started to take a life of its own since its inception in July 2000. We call it the ISIS juggernaut at San Francisco General Hospital (SFGH) because we have such a high volume that we are able to screen patients quickly and efficiently. When the clinic first opened up, the volume was 200 patients per month and now we are approaching about 500 patients a month. The volume has increased exponentially in the 4 years the clinic has been open. On average, 16 patients are treated 7 days a week in the clinic and we are closed on city holidays. The record number for number of patients screened in 1 day was 28 patients. Approximately 50% of the patients have procedures as we report in the manuscript.

The clinic has really decompressed hospital admissions burden and helped treat a huge public health burden in the city of San Francisco. San Francisco has the dubious distinction of having the No. 1 per capita incidence of injection drug use of any city in the United States. The clinic has consistently lowered OR volume each year. It has also improved the night call for the junior residents, since the attendings are now treating the lion share of the burden of the soft tissue infections at SFGH.

The clinic is a quick way for patients to see an attending surgeon at SFGH. A by-product at the clinic has been helping in other areas, like making the diagnosis of cancer in patients. As the reputation has grown, we have seen some mistriage from the emergency department and other hospitals in the city. We have actually been treating rashes and all kinds of other non-surgical problems. This problem is because we have been providing such a great service for the city and county of San Francisco. For example, we made the diagnosis of pregnancy in a patient who was assaulted and had abdominal and back pain.

Within the last 2 years, we have opened a Soft Tissue Mass Excision Clinic that has helped reduce the operating room burden of simple lipomas and cutaneous cyst excisions. Minor plastic surgical procedures are also performed in the clinic. The ISIS Clinic is a joint venture between the hospital, the Department of Surgery, and nurses, who are all responsible for making it work in such an efficient way. We appreciate the fact that Dr Organ came and visited the clinic to see how it really works on a daily basis. Jacquie Caesar, RN, the head nurse, does a tremendous job, and I will make sure to send her your greetings, Dr Organ.

Dr Margulies asked a question about what is our trigger for admission and how do we figure out whom to admit? At San Francisco General Hospital, as many of you know, we have a tremendous experience there in the surgery of sepsis. There is a long history of surgeons who have treated patients with these problems and published their results over the last 30 years. We have treated a large number of patients who have both simple infections and complicated infections. I don't want you to think we are only taking the easy infections here. We basically take all patients anytime that the clinic is open. On average, 5 to 10 patients who are admitted through ISIS and the emergency department will die of necrotizing soft tissue infection. No one to my knowledge has died since the clinic opened from a soft tissue infection seen in ISIS. The patients are quite sick, and we have a tremendous urgency to make sure that we do not miss soft tissue infections, particularly when we are treating patients in the outpatient setting. The triggers for admission include (1) elevated temperature, (2) heart rate elevation, (3) lymphangitis, and (4) coexisting comorbidities, including HIV and hepatitis C and other comorbidities such as elderly patients, patients with liver disease, and patients with renal failure, for example. For resistant infections, when we first started the clinic, we treated the patients with levofloxacin, which had a good response, but now the organisms that we have are resistant to levofloxacin over the last 3 years. We have not used Bactrim in our patient population to answer your question.

Dr Jolley, thank you for your question regarding MRSA. We switched over quickly to vancomycin to ensure that they get adequate therapy. Treatment depends on whether or not they have persistent spiking fevers or persistent elevations in their white count. The plan of therapy is based on the clinical experience of the surgeon taking care of the patients, because we do not draw blood tests on patients unless we decide to admit them to the hospital. The modality of treatment is all based on clinical impression, so it is really based on the experience of the surgeons who work in the ISIS Clinic and experience is quite tremendous as our data demonstrate.

Dr Alberty, I am not sure how many of our patients live in nursing homes. You have a tremendous rate of MRSA in your nursing home in your city. I cannot comment on that problem in San Francisco. It is interesting to note that obviously there are other reservoirs of this infection. This community reservoir includes nursing homes and other chronic care facilities in the city.

Dr Aye asked a question regarding whether or not our patients enjoyed being hospitalized at San Francisco General Hospital. It is true that our patients also like hospitalization at our

facility. The opportunity to have 3 square meals a day, a pillow under your head, and the chance to watch TV is better than being homeless. Eighty percent of our patients are uninsured or homeless. Our whole approach to treating patients with soft tissue infection is holistic. The patients actually like coming to the clinic; they know when it is open. They also have my call schedule so they know when I am there, which is quite unfortunate because I tend to have a lot more patients than some of the other physicians who work there. The patients like being treated in the clinic. It's an efficient way to have your infection treated in a humane fashion. They get their infection taken care of, and they don't have to sit in the emergency room for what is sometimes 10 or 12 hours to get cared for or get admitted to have a procedure. They know that even if they do get admitted that they will come to the ISIS Clinic and be cared for with respect. It's only in the cases of the severe infections when we think there is necrotizing fasciitis that the patients go on to the operating room to have their abscesses drained. We still have a number of patients who will go to the operating room to have surgery on a regular basis. This volume is a fraction of our volume pre ISIS.

Dr Albo, I don't think any of our homeless patients are ex-professional athletes the last time I checked. One patient told

me in our preprocedure interview that he played a few years of college ball as a running back. The problem of professional athletes and MRSA is an interesting observation. I am really interested in seeing what you have to report from your experience with professional athletes. We appreciate your comments.

Finally, Dr Wilson, I appreciate your comments regarding our paper. You asked, "Do we treat nosocomial infections different than community-acquired infections?" Again, everything really depends on the severity of the illness with the patients. Many times patients do come in and they are already floridly septic, because we have such a hard-core indigent patient population. Our patients typically do not seek treatment until the last possible moment. They present to the clinic, and we make the assessment and make sure they get appropriate therapy. If we think someone has a severe infection, we treat them with vancomycin initially. We will try to drain the large burden of their infection and get rid of it. You may think we only do small cases there in the clinic. Occasionally, we have drained at least a liter or more of pus out of these abscesses in the clinic.

In conclusion, I would like to thank the Pacific Coast Surgical Association for the privilege of the floor and I appreciate all the questions that were generated from the floor.

#### Announcement

**T**he *Archives of Surgery* will give priority review and early publication to seminal works. This policy will include basic science advancements in surgery and critically performed clinical research.